X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
tocilizumab (2338) 2338
humans (1144) 1144
rheumatology (898) 898
rheumatoid arthritis (889) 889
female (674) 674
male (582) 582
interleukin-6 (498) 498
antibodies, monoclonal, humanized - therapeutic use (495) 495
middle aged (491) 491
arthritis, rheumatoid - drug therapy (467) 467
treatment outcome (460) 460
double-blind (447) 447
adult (398) 398
antirheumatic agents - therapeutic use (386) 386
aged (352) 352
arthritis (336) 336
methotrexate (320) 320
therapy (284) 284
il-6 (269) 269
rheumatoid-arthritis (269) 269
immunology (252) 252
cytokines (242) 242
rituximab (236) 236
medicine & public health (234) 234
efficacy (232) 232
disease-activity (221) 221
inflammation (215) 215
rheumatoid factor (194) 194
safety (194) 194
infliximab (192) 192
abatacept (184) 184
disease (180) 180
etanercept (179) 179
drug therapy (178) 178
pharmacology & pharmacy (175) 175
inadequate response (173) 173
antibodies, monoclonal, humanized - adverse effects (170) 170
care and treatment (168) 168
interleukin 6 (168) 168
patients (165) 165
adalimumab (164) 164
juvenile idiopathic arthritis (159) 159
modifying antirheumatic drugs (157) 157
medicine, general & internal (155) 155
animals (151) 151
antibodies, monoclonal, humanized - administration & dosage (151) 151
antirheumatic agents - adverse effects (150) 150
receptors, interleukin-6 - antagonists & inhibitors (149) 149
interleukins (148) 148
internal medicine (146) 146
severity of illness index (146) 146
trial (145) 145
monoclonal antibodies (144) 144
remission (142) 142
giant cell arteritis (137) 137
antibodies, monoclonal - therapeutic use (133) 133
drug therapy, combination (133) 133
abridged index medicus (132) 132
musculoskeletal diseases (131) 131
analysis (127) 127
interleukin-6 - antagonists & inhibitors (122) 122
interleukin-6 receptor inhibition (117) 117
biologics (116) 116
retrospective studies (115) 115
antirheumatic agents - administration & dosage (111) 111
health aspects (109) 109
monotherapy (109) 109
corticosteroids (108) 108
anakinra (106) 106
antibodies, monoclonal, humanized (106) 106
treatment (104) 104
research (101) 101
skin and connective tissue diseases (100) 100
clinical trials (98) 98
tumor necrosis factor-tnf (98) 98
diagnosis (97) 97
multicenter (97) 97
methotrexate - therapeutic use (96) 96
antibody (95) 95
biological products - therapeutic use (94) 94
placebo-controlled trial (94) 94
tumor necrosis factor-alpha - antagonists & inhibitors (94) 94
antibodies, monoclonal, humanized - pharmacology (92) 92
management (92) 92
children (91) 91
takayasu arteritis (91) 91
monoclonal-antibody (90) 90
remission induction (90) 90
adolescent (89) 89
anti-interleukin-6 receptor antibody (89) 89
interleukin-6 - metabolism (89) 89
immunosuppressive agents - therapeutic use (87) 87
young adult (87) 87
pathogenesis (85) 85
receptors, interleukin-6 - immunology (84) 84
medical research (83) 83
time factors (83) 83
arthritis, rheumatoid - immunology (81) 81
c-reactive protein (81) 81
medicine (81) 81
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (2140) 2140
French (84) 84
German (56) 56
Japanese (56) 56
Russian (49) 49
Spanish (39) 39
Czech (12) 12
Portuguese (8) 8
Polish (6) 6
Chinese (5) 5
Korean (5) 5
Hungarian (4) 4
Italian (3) 3
Slovak (2) 2
Belarusian (1) 1
Estonian (1) 1
Icelandic (1) 1
Swedish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The oncologist (Dayton, Ohio), ISSN 1549-490X, 2018, Volume 23, Issue 8, pp. 943 - 947
On August 30, 2017, the U.S. Food and Drug Administration approved Actemra (tocilizumab, Genentech, Inc., South San Francisco, CA) for the treatment of severe... 
Cytokine release syndrome | Chimeric antigen receptor | Interleukin‐6 | Tocilizumab | T cell | Immunotherapy | Interleukin-6 | MANAGEMENT | ONCOLOGY | REMISSIONS | LEUKEMIA | FDA | Regulatory Issues
Journal Article
The Journal of allergy and clinical immunology, ISSN 0091-6749, 11/2018, Volume 142, Issue 5, pp. 1665 - 1669
Treatment of the autoimmune and immune-dysregulatory features of patients with STAT1 GOF or STAT3 GOF disease remains challenging. Jakinibs have been used to... 
Ruxolitinib | Tofacitinib | STAT1 | Tocilizumab | HLH | STAT3 | Jakinib
Journal Article
Cancer discovery, ISSN 2159-8290, 2017, Volume 7, Issue 12, pp. 1404 - 1419
Lymphodepletion chemotherapy followed by infusion of CD19-targeted chimeric antigen receptor-modified T (CAR-T) cells can be complicated by neurologic adverse... 
SUSTAINED REMISSIONS | MANAGEMENT | B-CELL | ONCOLOGY | THROMBOSIS | MALIGNANCIES | SERUM | CHIMERIC ANTIGEN RECEPTOR | LEUKEMIA | PERICYTES | TOCILIZUMAB | chimeric antigen receptor | neurotoxicity | cytokine release syndrome | CAR | CD19
Journal Article
Annals of the Rheumatic Diseases, ISSN 0003-4967, 02/2018, Volume 77, Issue 2, pp. 212 - 220
Journal Article
Journal Article
Rheumatology (Oxford, England), ISSN 1462-0324, 12/2017, Volume 57, Issue 3, pp. 499 - 507
The aim of this pooled analysis of the TOZURA study programme was to evaluate the efficacy and safety of subcutaneous tocilizumab (TCZ-SC) as monotherapy or in... 
tocilizumab | Clinical Science | biologic therapies | rheumatoid arthritis | csDMARDs
Journal Article
Rheumatology (Oxford, England), ISSN 1462-0332, 2018, Volume 57, Issue suppl_2, pp. ii43 - ii50
Journal Article
Rheumatology (Oxford, England), ISSN 1462-0324, 10/2017, Volume 56, Issue 10, pp. 1818 - 1819
Journal Article
International journal of molecular sciences, ISSN 1422-0067, 2018, Volume 19, Issue 11, p. 3528
Journal Article
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, ISSN 1083-8791, 10/2016, Volume 22, Issue 10, pp. 1851 - 1860
Use of high dose post-transplant cyclophosphamide for graft versus host disease (GVHD) prophylaxis has expanded the use of un-manipulated haploidentical... 
Haploidentical | CRS | Tocilizumab | TRM
Journal Article
Autoimmunity Reviews, ISSN 1568-9972, 2013, Volume 12, Issue 12, pp. 1143 - 1149
Abstract Background/purpose The aim of this study is to analyze the efficacy and tolerance of tocilizumab in patients with Takayasu arteritis (TA). Methods We... 
Allergy and Immunology | Tocilizumab | Treatment | Takayasu arteritis | INVOLVEMENT | PATIENT | IMMUNOLOGY | DISEASE-ACTIVITY
Journal Article